Concepedia

R. Insinga

RI

5

Publications

172

Citations

5

H-Index

2008

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

R. Insinga is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, lung cancer, and cancer therapeutics.

Top concepts

Publications per year

2008–2020

5

Publications

5

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK

EJ Dasbach, R. Insinga, EH Elbasha · BJOG An International Journal of Obstetrics & Gynaecology · 2008 · 89 citations

Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years

Ankita Modi, S. Sajjan, R. Insinga et al. · Osteoporosis International · 2017 · 37 citations

, , +7

PCN41 Cost-Effectiveness of Pembrolizumab in Combination with Chemotherapy in the 1ST LINE Treatment of Metastatic NSCLC in Taiwan

R. Insinga, Ashwini Arunachalam, Siyuan Lei et al. · Value in Health Regional Issues · 2020 · 17 citations · Full text

PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France

C. Chouaïd, L. Bensimon, J. Tardu et al. · Value in Health · 2020 · 17 citations

PCN345 - HEALTH STATE UTILITIES IN METASTATIC NSCLC: A STUDY OF MULTIPLE IMMUNO-ONCOLOGY TRIALS

Mei‐Chih Huang, Sheenu Chandwani, R. Insinga et al. · Value in Health · 2018 · 12 citations

, , +5

Rows per page

1–5 of 5